However, the anti-PD-1/PD-L1 or anti-CTLA-4 antibodies were not approved for HCC patients in 2012, therefore we were not able to analyse the relationship of the response to immunotherapy and apoE in HCC patients, which was a limitation of this research. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.